Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Breast Neoplasms 4Brain Neoplasms 4Prostatic Neoplasms 3Neoplasms 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Pinealoma 1Parotid Neoplasms 1Oligodendroglioma 1Neuroendocrine Tumors 1Neuroectodermal Tumors, Primitive 1Multiple Sclerosis 1Meningioma 1Meningeal Neoplasms 1Medulloblastoma 1Lymphoma 1Liver Neoplasms 1Hypoxia 1Gynecologic Cancer 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Digestive System Diseases 1Colorectal Neoplasms 1Choroid Plexus Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Brain Tumor Adult 1

Interventions

Temozolomide 11Cyclophosphamide 11Radiotherapy 7Magnetic Resonance Spectroscopy 6Filgrastim 6Cisplatin 6Vincristine 5Etoposide 5Carboplatin 5antineoplaston AS 2-1 4antineoplaston A10 4sargramostim 3Thiotepa 3Melphalan 3Carmustine 3Automobiles 32-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 3gallium Ga 68 dotatate 2fludarabine 2dactolisib 2aldesleukin 2Thalidomide 2TH 302 2Surveys and Questionnaires 2Paclitaxel 2Irinotecan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Gadolinium DTPA 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × gadobutrol × Clear all
NCT02967380 2017-03-27

Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases

University of Southern California

Phase NA Terminated
14 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Multiple Sclerosis, Oligodendroglioma, Pinealoma, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡